CliffBio
biologic

Luxturna

Voretigene Neparvovec

Loss of exclusivityDecember 2029projected — 12-year biologic exclusivity estimate
CompanySpark →See this company's full patent-cliff portfolio

Drug detail

Brand nameLuxturna
Active ingredientVoretigene Neparvovec
Strength1.5X10 TO 11 ML
Dosage formInjection
RouteIntraocular
ModalityBiologic
FDA approvalDecember 2017
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Luxturna patent cliff — loss of exclusivity December 2029 | CliffBio